Laboratorios Del Dr. Esteve S.a.

Esteve Pharmaceuticals, S.a.

Laboratories Del Dr. Esteve S.a.

Antoni Torrens-Jover

Carmen Almansa-Rosales

Jordi Frigola-Constansa

Helmut Heinrich Buschmann

Monica Garcia-Lopez

Carmen Almansa Rosales

Josep Mas-Prio

Ute Christmann

Susana Yenes-Minguez

Miguel Angel Pericas-Brondo

Jordi Benet-Buchholz

Ana-Maria Caamaño-Moure

Èric Ferrer-Mallofrè

Jordi Carles Ceron-Bertran

Lluis Sola-Carandell

Félix Cuevas-Cordobes

Àlex Pericas-Cano

Rosa Ortuño-Mingarro

Josè-Luis Diaz-Fernández

Jose-Luis Diaz-Fernández

Pilar Goya

Felix Cuevas-Cordobes

José-Luis Diaz-Fernandez

The present invention relates to 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethy)piperazin-1-y)ethanone salts, specifically to the hydrochloride and to the maleate, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor associated diseases.

1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-Yl)methoxy)ethyl)piperazin-1- Yl)ethanone salts

The present invention relates to arylamide derivatives having dual pharmacological activity towards both the &#x3b1;2&#x3b4; subunit, in particular the &#x3b1;2&#x3b4;-1 subunit, of the voltage-gated calcium channel and the &#x3bc;-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Arylamide derivatives having multimodal activity against pain

The present invention relates to compounds having dual pharmacological activity towards both the sigma (&#x3c3;) receptor, and the &#x3bc;-opiod receptor and more particularly to methyl-1H-pyrazole alkylamine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain

The present invention relates to new 1,2,3-triazole-amine derivatives, having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for the treatment of sigma receptor related diseases and disorders.

1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders

The invention refers to compounds of general formula (I) 

1,2-disubstituted cyclobutyl compounds

The present invention relates to new tricyclic triazolic compounds having a high affinity for sigma-1 receptor as well as to the process for the preparation thereof, to composition comprising them and to their use as medicaments according to compounds of formula (I), Wherein Rand Rare as defined in the description. 

Tricyclic triazolic compounds

The present invention concerns salts of Tramadol and Naproxen and their crystalline forms, and compositions thereof, for the treatment of pain, as well as their process for preparation.

Salts of Tramadol and Naproxen and their crystal forms in the treatment of pain

The procedure comprises reacting the mixture that comprises 2-&lsqb;phenyl(1-methyl-1 H-pyrazole-5-yl)methoxy&rsqb;-N,N-dimethylethanamine (I) with an enantiomer of an optically active acid to form a diastereoisomeric salt, separating said salt and liberating the enantiomer of said compound (I). The dextrorotatory enantiomer of (I) can be obtained by reacting a racemic mixture or non-racemic mixture of (I) with (&plus;)-ditoluyl-L-tartaric acid, optionally mixed with p-toluensulphonic acid. Compound (I) has analgesic properties and its most active enantiomer is dextrorotatory.

Resolution of amines

Process for obtaining enantiomers of cis-olirtine

Growing community of inventors

Terrassa, Spain

Antoni Torrens-Jover